User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

CYP3A4*22is related to increased plasma levels of 4-hydroxytamoxifen and partially compensates for reduced CYP2D6 activation of tamoxifen

  1. Brauch H., Murdter T. E., Eichelbaum M., Schwab M., Pharmacogenomics of Tamoxifen Therapy, 10.1373/clinchem.2008.121756
  2. Jung Jin-A, Lim Hyeong-Seok, Association betweenCYP2D6genotypes and the clinical outcomes of adjuvant tamoxifen for breast cancer: a meta-analysis, 10.2217/pgs.13.221
  3. JORDAN V. C., COLLINS M. M., ROWSBY L., PRESTWICH G., A MONOHYDROXYLATED METABOLITE OF TAMOXIFEN WITH POTENT ANTIOESTROGENIC ACTIVITY, 10.1677/joe.0.0750305
  4. Teunissen S.F., Rosing H., Koornstra R.H.T., Linn S.C., Schellens J.H.M., Schinkel A.H., Beijnen J.H., Development and validation of a quantitative assay for the analysis of tamoxifen with its four main metabolites and the flavonoids daidzein, genistein and glycitein in human serum using liquid chromatography coupled with tandem mass spectrometry, 10.1016/j.jchromb.2009.06.029
  5. Mürdter T E, Schroth W, Bacchus-Gerybadze L, Winter S, Heinkele G, Simon W, Fasching P A, Fehm T, Eichelbaum M, Schwab M, Brauch H, Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma, 10.1038/clpt.2011.27
  6. Ahsen NV, J. Lab. Med., 33, 1 (2009)
  7. Madlensky L, Natarajan L, Tchu S, Pu M, Mortimer J, Flatt S W, Nikoloff D M, Hillman G, Fontecha M R, Lawrence H J, Parker B A, Wu A H B, Pierce J P, Tamoxifen Metabolite Concentrations, CYP2D6 Genotype, and Breast Cancer Outcomes, 10.1038/clpt.2011.32
  8. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS, The CYP2D6 Activity Score: Translating Genotype Information into a Qualitative Measure of Phenotype, 10.1038/sj.clpt.6100406
  9. Borges Silvana, Desta Zeruesenay, Jin Yan, Faouzi Azzouz, Robarge Jason D., Philip Santosh, Nguyen Anne, Stearns Vered, Hayes Daniel, Rae James M., Skaar Todd C., Flockhart David A., Li Lang, Composite Functional Genetic and Comedication CYP2D6 Activity Score in Predicting Tamoxifen Drug Exposure Among Breast Cancer Patients, 10.1177/0091270009359182
  10. Teh Lay Kek, Bertilsson Leif, Pharmacogenomics of CYP2D6: Molecular Genetics, Interethnic Differences and Clinical Importance, 10.2133/dmpk.dmpk-11-rv-121
  11. Kohlrausch Fabiana B, Gama Clarissa S, Lobato Maria Inês, Belmonte-de-Abreu Paulo, Gesteira Alejandro, Barros Francisco, Carracedo Angel, Hutz Mara H, Molecular diversity at theCYP2D6locus in healthy and schizophrenic southern Brazilians, 10.2217/pgs.09.76
  12. Friedrich Deise C., Genro Júlia P., Sortica Vinicius A., Suarez-Kurtz Guilherme, de Moraes Maria Elizabete, Pena Sergio D. J., dos Santos Ândrea K. Ribeiro, Romano-Silva Marco A., Hutz Mara H., Distribution of CYP2D6 Alleles and Phenotypes in the Brazilian Population, 10.1371/journal.pone.0110691
  13. Antunes Marina V., Linden Rafael, Santos Tamyris V., Wallemacq Pierre, Haufroid Vincent, Classen Jean-François, Andreolla Huander, Costa Nathalia, Fontanive Tiago O., Rosa Daniela D., Endoxifen Levels and Its Association With CYP2D6 Genotype and Phenotype : Evaluation of a Southern Brazilian Population Under Tamoxifen Pharmacotherapy, 10.1097/ftd.0b013e318260b46e
  14. Irvin William J., Walko Christine M., Weck Karen E., Ibrahim Joseph G., Chiu Wing K., Dees E. Claire, Moore Susan G., Olajide Oludamilola A., Graham Mark L., Canale Sean T., Raab Rachel E., Corso Steven W., Peppercorn Jeffrey M., Anderson Steven M., Friedman Kenneth J., Ogburn Evan T., Desta Zeruesenay, Flockhart David A., McLeod Howard L., Evans James P., Carey Lisa A., Genotype-Guided Tamoxifen Dosing Increases Active Metabolite Exposure in Women With Reduced CYP2D6 Metabolism: A Multicenter Study, 10.1200/jco.2010.31.4427
  15. Musshoff Frank, Stamer Ulrike M., Madea Burkhard, Pharmacogenetics and forensic toxicology, 10.1016/j.forsciint.2010.07.011
  16. Wang Zhican, Schuetz Erin G., Xu Yang, Thummel Kenneth E., Interplay between vitamin D and the drug metabolizing enzyme CYP3A4, 10.1016/j.jsbmb.2012.09.012
  17. Wang D, Guo Y, Wrighton S A, Cooke G E, Sadee W, Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs, 10.1038/tpj.2010.28
  18. Teft Wendy A., Gong Inna Y., Dingle Brian, Potvin Kylea, Younus Jawaid, Vandenberg Theodore A., Brackstone Muriel, Perera Francisco E., Choi Yun-Hee, Zou Guangyong, Legan Robin M., Tirona Rommel G., Kim Richard B., CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy, 10.1007/s10549-013-2511-4
  19. ter Heine Rob, Binkhorst Lisette, de Graan Anne Joy M., de Bruijn Peter, Beijnen Jos H., Mathijssen Ron H. J., Huitema Alwin D. R., Population pharmacokinetic modelling to assess the impact of CYP2D6 and CYP3A metabolic phenotypes on the pharmacokinetics of tamoxifen and endoxifen : Impact of metabolic phenotype on tamoxifen pharmacokinetics, 10.1111/bcp.12388
  20. Elens Laure, van Schaik Ron H, Panin Nadtha, de Meyer Martine, Wallemacq Pierre, Lison Dominique, Mourad Michel, Haufroid Vincent, Effect of a new functionalCYP3A4polymorphism on calcineurin inhibitors’ dose requirements and trough blood levels in stable renal transplant patients, 10.2217/pgs.11.90
  21. Antunes Marina Venzon, Raymundo Suziane, de Oliveira Vanessa, Staudt Dilana Elisabeth, Gössling Gustavo, Peteffi Giovana Piva, Biazús Jorge Villanova, Cavalheiro José Antônio, Tre-Hardy Marie, Capron Arnaud, Haufroid Vincent, Wallemacq Pierre, Schwartsmann Gilberto, Linden Rafael, Ultra-high performance liquid chromatography tandem mass spectrometric method for the determination of tamoxifen, N -desmethyltamoxifen, 4-hydroxytamoxifen and endoxifen in dried blood spots—Development, validation and clinical application during breast cancer adjuvant therapy, 10.1016/j.talanta.2014.10.040
  22. Bijl Monique J., van Schaik Ron H. N., Lammers Laureen A., Hofman Albert, Vulto Arnold G., van Gelder Teun, Stricker Bruno H. Ch., Visser Loes E., The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users, 10.1007/s10549-008-0272-2
  23. Schroth Werner, Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen, 10.1001/jama.2009.1420
  24. Jager N. G. L., Rosing H., Schellens J. H. M., Linn S. C., Beijnen J. H., Tamoxifen dose and serum concentrations of tamoxifen and six of its metabolites in routine clinical outpatient care, 10.1007/s10549-013-2826-1
  25. Heath D.D., Flatt S.W., Wu A. H. B., Pruitt M. A., Rock C. L., Evaluation of Tamoxifen and Metabolites by LC-MS/MS and HPLC Methods, 10.1080/09674845.2014.11669960
Bibliographic reference Antunes, Marina Venzon ; de Oliveira, Vanessa ; Raymundo, Suziane ; Staudt, Dilana Elisabeth ; Gössling, Gustavo ; et. al. CYP3A4*22is related to increased plasma levels of 4-hydroxytamoxifen and partially compensates for reduced CYP2D6 activation of tamoxifen. In: Pharmacogenomics, Vol. 16, no. 6, p. 601-617 (2015)
Permanent URL http://hdl.handle.net/2078.1/164936